News & Updates

Adherence to lenalidomide deficient in multiple myeloma patients

07 Feb 2022

Adherence to lenalidomide is remarkably lacking among patients with multiple myeloma at 1 year following treatment initiation, a study has found.

Adherence to lenalidomide deficient in multiple myeloma patients

07 Feb 2022

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

07 Feb 2022

The addition of mogamulizumab to nivolumab falls short of improving efficacy of the latter in the treatment of patients with locally advanced or metastatic solid tumours, according to the results of a phase I/II trial.

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

07 Feb 2022

Efavirenz efficacy not compromised when switched to lower dose

06 Feb 2022

In the management of virologically suppressed patients living with HIV, efavirenz 400 mg has noninferior efficacy and favourable safety as compared with the 600 mg-based regimen, according to a study from China.

Efavirenz efficacy not compromised when switched to lower dose

06 Feb 2022

RhNGF eye drops safe but does not confer significant neuroenhancement in glaucoma

05 Feb 2022

Treatment with topical recombinant human nerve growth factor (rhNGF) is safe and well tolerated but falls short of providing neuroprotection in patients with glaucoma, according to the results of a phase Ib study.

RhNGF eye drops safe but does not confer significant neuroenhancement in glaucoma

05 Feb 2022

Adjuvant S-1 ups survival in resected biliary tract cancer

05 Feb 2022 by

Giving adjuvant S-1 to patients with curatively resected biliary tract cancer (BTC) significantly improves survival compared with observation following surgery, according to the ASCOT trial presented in the 2022 ASCO Gastrointestinal Cancers Symposium (GICS).

Adjuvant S-1 ups survival in resected biliary tract cancer

05 Feb 2022

On-body injector on par with traditional injection in preventing severe neutropaenia

05 Feb 2022

Pegfilgrastim on-body injectors (OBI) are as effective as traditional injection for the prevention of severe neutropaenia (SN), neutropaenic fever, and neutropaenia in breast cancer patients, reveals a study.

On-body injector on par with traditional injection in preventing severe neutropaenia

05 Feb 2022

Obese breast cancer patients on T-DM1 prone to more treatment adjustments

04 Feb 2022

More treatment modifications secondary to adverse events appear necessary among obese patients receiving ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer, relative to nonobese counterparts, reports a study.

Obese breast cancer patients on T-DM1 prone to more treatment adjustments

04 Feb 2022

10-day antibiotic therapy noninferior to 14 days for GNB sepsis

04 Feb 2022

Antibiotic therapy for 10 days is not inferior to 14 days therapy in nonvery low birth weight (non-VLBW) infants with Gram-negative bacterial (GNB) sepsis, a recent study has shown.

10-day antibiotic therapy noninferior to 14 days for GNB sepsis

04 Feb 2022

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

Heart failure (HF) is a complicated clinical syndrome that is inherently progressive. In HF with reduced ejection fraction (HFrEF), the left ventricular ejection fraction (LVEF) is ≤40 percent and accompanied by progressive LV dilatation and adverse cardiac remodeling. [Eur J Heart Fail 2021;23:352-380]

Vericiguat addresses unmet needs in worsening HFrEF

04 Feb 2022

Elevated vitamin B12 levels confer insomnia risk in diabetic patients

03 Feb 2022

Vitamin B12 concentrations in type 2 diabetes mellitus (T2DM) patients are linked to the incidence of insomnia and help pinpoint those who are likely to develop the condition according to a study.

Elevated vitamin B12 levels confer insomnia risk in diabetic patients

03 Feb 2022

News & Updates

Filter by Specialty:

Specialty:

Adherence to lenalidomide deficient in multiple myeloma patients

Adherence to lenalidomide deficient in multiple myeloma patients

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

Combining mogamulizumab with nivolumab of no benefit in advanced solid tumours

Efavirenz efficacy not compromised when switched to lower dose

Efavirenz efficacy not compromised when switched to lower dose

RhNGF eye drops safe but does not confer significant neuroenhancement in glaucoma

RhNGF eye drops safe but does not confer significant neuroenhancement in glaucoma

Adjuvant S-1 ups survival in resected biliary tract cancer

Adjuvant S-1 ups survival in resected biliary tract cancer

On-body injector on par with traditional injection in preventing severe neutropaenia

On-body injector on par with traditional injection in preventing severe neutropaenia

Obese breast cancer patients on T-DM1 prone to more treatment adjustments

Obese breast cancer patients on T-DM1 prone to more treatment adjustments

10-day antibiotic therapy noninferior to 14 days for GNB sepsis

10-day antibiotic therapy noninferior to 14 days for GNB sepsis

Vericiguat addresses unmet needs in worsening HFrEF

Vericiguat addresses unmet needs in worsening HFrEF

Elevated vitamin B12 levels confer insomnia risk in diabetic patients

Elevated vitamin B12 levels confer insomnia risk in diabetic patients